

Medical Innovations

PATENT *mitra*

Patent and Technology Transfer Enabler

NEWSLETTER

Edition 1, June 2025

Key Highlights:

- Medical Innovations Drive
- Patent Spotlight
- Technology Byte

What's New:

- 1st Technology Transfer Deal
- Innovator's Corner
- Technologies Available for Transfer

Editorial

Every breakthrough in health begins with an idea, and every idea deserves protection. With this inaugural issue of Medical Innovations Patent Mitra, we launch more than a newsletter: we begin a mission to support and strengthen the IP journey of India's medical innovators.

Medical Innovations Patent Mitra, a collaborative initiative of ICMR, Department of Pharmaceuticals (DoP), Department for Promotion of Industry and Internal Trade (DPIIT) and NITI Aayog; envisage to bridge the gap between research and real-world solutions. It equips researchers with the guidance, tools, and resources needed to protect their ideas, understand IP rights, and navigate technology transfer.

More than just a support system, Patent Mitra fosters a culture of innovation across ICMR institutes, its extramural grantees and medical colleges, helping researchers take ownership of their research work and scale its significance.

This newsletter will highlight the progress of this national initiative, share insights, and showcase opportunities and success stories, reinforcing its commitment to translating innovations for societal impact.




Medical Innovations Patent Mitra

Medical Innovations Patent Mitra, initiative aims to provide expert guidance and comprehensive support to innovators in biomedical domain, facilitating patent filings and technology transfer of medical innovations, thereby strengthening the innovation ecosystem of India.



Vision

To build a robust and dynamic ecosystem that nurtures innovation, translating biomedical research into practical and tangible solutions that drive transformative advancements in public health across India.



Mission

To support strategic and quality patent filings for innovative biomedical research and facilitating seamless technology transfer to industry for societal impact.

Benefits for the Innovators

Zero Cost Patent Filing:

- The initiative offers end-to-end guidance for patent filings, at zero cost to innovator.

Enable Technology Transfer:

- Facilitation for seamless technology transfer for public access, thereby increasing their societal impact.

Intellectual Property Expert Support:

- Innovators will receive subject matter expert-driven support.

Online IP Management:

- Online systems for transparent and paperless process.

Capacity Building:

- Training innovators to build capacity among researchers and institutions, enhancing their ability to navigate the patent landscape.

Medical Innovation Drive

Awareness Creation Sessions

- ✓ 2 awareness sessions conducted across the extramural grantees and medical colleges/institutes.
- ✓ 300+ innovators trained on IP basics, filing process, and technology transfer through Patent Mitra.



From Lab to Market: Evaluating Commercial Potential

- ✓ An innovation drive was undertaken to assess technology readiness, resulting in the shortlisting of technologies from a portfolio of over 200 patent applications.



Patent Mitra Technology Transfer in Action

Salmonella Vaccine Technology

Medical Innovations Patent Mitra facilitated transfer of Salmonella Vaccine Technology Developed by ICMR-NIRBI Kolkata for Typhoid, Paratyphoid, and Salmonella Typhimurium gastroenteritis to Panacea Biotec Limited on June 4, 2025. The licensing ceremony was graced by Dr. V K Paul, Member, NITI Aayog, Dr. Rajiv Bahl, Secretary, DHR & DG, ICMR, Mr. Amit Agrawal, Secretary, Department of Pharmaceuticals, Dr. Unnat Pandit, Controller General of Patents, Designs and Trade Marks, Dr. B N Gangadhar, Chairperson, National Medical Commission, & Dr. Srinivas, Director, All India Institute of Medical Sciences (AIIMS).



Technologies available for Transfer

DIAGNOSTICS

- ✓ **AFuPEPLISA Immunodiagnostic Kit** Developed by ICMR-NIRRH to detect *Aspergillus fumigatus* antibodies in asthma and TB patients. Patent protected (IN 202411008706)
- high sensitivity,
 - low variability,
 - and cost-effective for district hospitals.

VACCINE CANDIDATES

✓ **Novel Shigella Vaccine:**

ICMR-NIRBI's vaccine targets multiple *Shigella* serotypes using Multi-Serotype Outer Membrane Vesicles (MOMV), overcoming antigenic diversity. Patent protected (PCT/IN2014/000369).

Patent Spotlight

Delhi High Court Rules in Favor of Public Interest in Risdiplam Case:

The Delhi High Court recently denied Roche's request for an interim injunction to block Natco from manufacturing Risdiplam, a drug for spinal muscular atrophy (SMA). The Court allowed Natco to produce the drug locally, provided detailed records are kept, and damages are paid if Roche prevails in the final verdict.



The case centers on Roche's species patent (IN334397) for Risdiplam, which the Court found was implicitly disclosed in an earlier genus patent (WO2013/119916A2). Roche does not manufacture the drug in India, where its high price (~₹1.48 crore/year) limits access. The Court prioritized public health and access to affordable treatment over patent rights.

An appeal is ongoing, with the Divisional Bench maintaining the status quo until the final decision.

Coming soon..

Distinguished Lecture by:



Prof. Unnat P. Pandit

Controller General of Patents, Designs, and Trademarks (CGPDTM)

What our Innovators say:



Our Collaborators



Under the guidance of



Department of Health Research
Ministry of Health and Family Welfare
Government of India

Supported by



उद्योग संवर्धन और आंतरिक व्यापार विभाग
DEPARTMENT FOR
PROMOTION OF INDUSTRY AND
INTERNAL TRADE